SINOMAB BIO-B(03681) completes disposal of Suzhou property and facilities

SINOMAB BIO-B (03681) announced that, in relation to the proposed disposal of the Suzhou property and facilities by its subsidiary for RMB280 million, the board is pleased to announce that all conditions precedent set out in the sale and purchase agreement have been fulfilled, and the disposal was completed on November 4, 2026 in accordance with the terms and conditions of the sale and purchase agreement. Upon completion, the target assets are no longer owned by the seller, and the company no longer has any interest in the target assets. The board believes that the completion of the disposal of the target assets reflects the group's firm determination to transform to an asset-light model, which will optimize resource allocation and enhance operational flexibility. In addition, adhering to the principle of differentiated innovation, the group will prioritize resources for early-stage research and clinical development, thereby maximizing long-term returns for shareholders.